Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
The license is valid for five years, effective from April 9, 2026
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
Subscribe To Our Newsletter & Stay Updated
